Torsdag 8 Oktober | 00:41:33 Europe / Stockholm
Est. tid*
2027-05-20 N/A Årsstämma
2027-02-17 08:55 Bokslutskommuniké 2026
2026-11-11 08:00 Kvartalsrapport 2026-Q3
2026-08-19 - Kvartalsrapport 2026-Q2
2026-05-22 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2026-05-21 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2026-01-19 - Extra Bolagsstämma 2026
2025-11-20 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2025-05-22 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Issuance and repurchase of class C shares for incentive program

2026-10-07 19:00:00

The board of directors of Cinclus Pharma Holding AB (publ) has today resolved to issue a total of 1,000,000 new class C shares and to immediately thereafter repurchase such 1,000,000 issued class C shares, for the purpose of the outstanding long term incentive program Performance Share Program 2026/2029. Today’s resolution by the board of directors was passed based on the authorization granted by the annual general meeting held on 21 May 2026.

Nordic Issuing AB will subscribe for all issued class C shares at a subscription price of approximately SEK 0.019413 per share, equal to the quota value of the shares. All 1,000,000 issued class C shares will be repurchased by Cinclus Pharma Holding AB (publ) for the same price per share. Following the share issue, the share capital will increase by SEK 19,413.284916. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.
 
The purpose of the issue and repurchase is to ensure future delivery of shares to participants in, as well as to cover any costs for social contributions arising as a result of, Performance Share Program 2026/2029. The class C shares will be reclassified to ordinary shares before delivery to the participants in the program.
 
Cinclus Pharma Holding AB (publ) will, following the issuance and repurchase of the 1,000,000 class C shares, hold all class C shares in the company.